Celgene logo Celgene Logo
Search

  • United States
    • Australia
      • English
    • Austria
      • Deutsch
    • Belgium
      • Français
      • Nederlands
    • Brazil
      • Português
    • Canada
      • English
      • Français
    • China
      • 简体中文
    • Czech Republic
      • Čeština
    • Denmark
      • Dansk
    • Europe
      • English
    • Finland
      • Suomi
    • France
      • Français
    • Germany
      • Deutsch
    • Hungary
      • Magyar
    • Ireland
      • English
    • Italy
      • Italiano
    • Japan
      • 日本語
    • Luxembourg
      • Français
      • Nederlands
    • Malaysia
      • English
    • Mexico
      • Español
    • Netherlands
      • Nederlands
    • Norway
      • Norsk
    • Poland
      • Polski
    • Portugal
      • Português
    • Russia
      • Русский язык
    • Singapore
      • English
    • Slovakia
      • Slovenčina
    • Slovenia
      • Slovenčina
    • South Korea
      • 한국어
    • Spain
      • Español
    • Sweden
      • Svenska
    • Switzerland
      • Deutsch
      • Français
    • Taiwan
      • 繁體中文
    • Thailand
      • English
    • Turkey
      • Türk
    • United Kingdom
      • English
    • United States
      • English
  • About
    • Our Story
    • Awards & Recognition
    • Celgene History
    • Our Culture
    • Our Employees
    • Leadership
      • Executive Committee
      • Board of Directors
    • Compliance
      • Code of Business Conduct and Ethics
      • Sunshine Act FAQ
      • California Declaration of Compliance
      • Vermont Prescriber Information
      • Authorized Distributor of Record Listing
      • General Conformity Certifications for Celgene Products
    • Corporate Reports
    • Diversity
    • Global Office Locations
      • Celgene Worldwide Markets
  • Diseases
    • Acute Myeloid Leukemia
    • Beta Thalassemia
    • Indolent NHL
    • Multiple Myeloma
      • Celgene Resources for Multiple Myeloma
      • Multiple Myeloma Timeline
    • Multiple Sclerosis
    • Myelodysplastic Syndromes
    • Myelofibrosis
    • Pancreatic Cancer
      • Celgene Resources for Pancreatic Cancer
    • Psoriasis and Psoriatic Arthritis
  • Therapies
    • Safety Data Sheets
    • Anti-counterfeiting
  • Research & Development
    • Pipeline
    • Medical Innovation
      • IMiDs
      • Anti-inflammatory Compounds
    • R&D Locations
    • Research Oncology
    • Celgene Incubator
    • Clinical Trials
      • Celgene-sponsored Trials
      • Investigator-initiated Trials
      • Clinical Trials Data Sharing
    • Celgene Global Drug Safety and Risk Management
      • Chrysalis
      • Publications
      • Safeguarding through Science: The GDSRM Value Story
    • Pre-Approval Access
    • Celgene Medical Affairs
      • Medical Affairs Grants
        • Independent Medical Education Grants
        • Scientific Advancement Grants
      • Celgene Medical Information
        • Medical Information Request Form
    • Registry Studies
  • Responsibility
    • Our Approach
      • Message from the Chairman and CEO
      • Materiality
      • Corporate Responsibility at Celgene
      • Celgene and the Sustainable Development Goals
      • External Recognition
    • Patients First
      • Patient Safety, Support & Advocacy
        • Patient Safety
        • Research & Development
        • Innovation Impact Awards
        • Advocacy Partnerships
        • Celgene Cooperation With European Patient Organizations
        • EFPIA Spend Transparency Disclosure
    • Pre-Approval Access
    • Patient Support
    • Global Health
      • Access Accelerated
      • Celgene Cancer Care Links™
      • Building Healthcare Capacity for Patients in Africa: AMPATH
      • Neglected Tropical Diseases
      • R&D for Neglected Tropical Diseases
    • Employees and Communities
      • Employees
        • Our Culture and Values
        • Employee Safety
        • Employee Benefits and Wellness
        • Diversity and Inclusion
      • Celgene Community Initiatives
    • Funding
      • Healthcare Related Donations
      • Charitable & Philanthropic Donations
      • Sponsorships
      • Corporate Memberships
      • Exhibits
      • Independent Medical Education Grants
      • Scientific Advancement Grants
      • Funding FAQs
      • Funding Contact Us
    • Business with Integrity
      • Governance
        • Sustainability & CR Governance
      • Ethics and Business Conduct
        • Reportable Allegations
        • Filing an Online Report
        • Country Access Codes
      • Public Policy
        • Public Policy Priorities
        • Association Memberships
        • Political Contributions
      • Supply Chain
        • Suppliers
        • Suppliers Form
    • Environment
      • 2020 Environmental Goals
      • Environmental Management
        • Building Sustainably
        • CDP (Carbon Disclosure Project)
  • Value
    • Value and Innovation Framework Report
    • Celgene Pricing Principles
  • Newsroom
    • Media Contacts
    • Multimedia Library
      • REMS Fact Sheet
      • Celgene Position Papers
    • Press Releases
    • Cellular Immunotherapies
  • Patients
    • Celgene Patient Support®
    • Online Patient Resources
    • REMS – Pharmacy Network
    • Glossary
  • Medical Professionals
    • Celgene Medical Information
  • Partnering
    • Philosophy to Partnering
    • Areas of Interest
    • Partner with Celgene
  • Investors
  • Careers
  • Contact Us
  • Celgene Highlights Patient Care Experience and Hope During World AML Awareness Day Celgene Highlights Patient Care Experience and Hope During World AML Awareness Day Celgene Highlights Patient Care Experience and Hope During World AML Awareness Day
    April 18, 2019

    Celgene Highlights Patient Care Experience and Hope During World AML Awareness Day

    Watch our Facebook Live Discussion with Anna Ferguson, RN, BSN to Learn More
    Read More
    • Share on Twitter
    • Share on Facebook
    • Share on LinkedIn
    • Share on Pinterest
  • Celgene and Bristol-Myers Squibb Stockholders Approve Combination to Create Innovative Biopharma Leader with Global Reach and ScaleCelgene and Bristol-Myers Squibb Stockholders Approve Combination to Create Innovative Biopharma Leader with Global Reach and ScaleCelgene and Bristol-Myers Squibb Stockholders Approve Combination to Create Innovative Biopharma Leader with Global Reach and Scale

    ​Celgene and Bristol-Myers Squibb Stockholders Approve Combination
    to Create Innovative Biopharma Leader with Global Reach and Scale ​
    READ MORE
  • Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment
    April 3, 2019

    Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment

    Read More
    • Share on Twitter
    • Share on Facebook
    • Share on LinkedIn
    • Share on Pinterest
  • The Human Rights Campaign Foundation Names Celgene Best Place to Work for LGBTQ Equality for 2019 The Human Rights Campaign Foundation Names Celgene Best Place to Work for LGBTQ Equality for 2019 The Human Rights Campaign Foundation Names Celgene Best Place to Work for LGBTQ Equality for 2019
    March 28, 2019

    Celgene Named Best Place to Work
    for LGBTQ Equality

    Read More
    • Share on Twitter
    • Share on Facebook
    • Share on LinkedIn
    • Share on Pinterest
  • Moving Mountains: How One Multiple Myeloma Patient Defied the Odds Moving Mountains: How One Multiple Myeloma Patient Defied the Odds Moving Mountains: How One Multiple Myeloma Patient Defied the Odds
    March 26, 2019

    Moving Mountains How One Multiple Myeloma
    Patient Defied the Odds

    Read More
    • Share on Twitter
    • Share on Facebook
    • Share on LinkedIn
    • Share on Pinterest

Celgene Highlights Patient Care Experience and Hope During World AML Awareness Day
April 18, 2019

Celgene Highlights Patient Care Experience and Hope During World AML Awareness Day

  • Share on Twitter
  • Share on Facebook
  • Share on LinkedIn
  • Share on Pinterest
Celgene and Bristol-Myers Squibb Stockholders Approve Combination to Create Innovative Biopharma Leader with Global Reach and Scale
April 12, 2019

Celgene and Bristol-Myers Squibb Stockholders Approve Combination to Create Innovative Biopharma Leader with Global Reach and Scale

  • Share on Twitter
  • Share on Facebook
  • Share on LinkedIn
  • Share on Pinterest
Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment
April 3, 2019

Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment

  • Share on Twitter
  • Share on Facebook
  • Share on LinkedIn
  • Share on Pinterest
The Human Rights Campaign Foundation Names Celgene Best Place to Work for LGBTQ Equality for 2019
March 28, 2019

The Human Rights Campaign Foundation Names Celgene Best Place to Work for LGBTQ Equality for 2019

  • Share on Twitter
  • Share on Facebook
  • Share on LinkedIn
  • Share on Pinterest
Moving Mountains: How One Multiple Myeloma Patient Defied the Odds
March 26, 2019

Moving Mountains: How One Multiple Myeloma Patient Defied the Odds

  • Share on Twitter
  • Share on Facebook
  • Share on LinkedIn
  • Share on Pinterest
Why Myelofibrosis Remains Difficult to Treat
March 25, 2019

Why Myelofibrosis Remains Difficult to Treat

  • Share on Twitter
  • Share on Facebook
  • Share on LinkedIn
  • Share on Pinterest

AroundtheWeb

  • Carl June, MD, Named One of Time Magazine’s Most Influential People

    Carl June, MD, Named One of Time Magazine’s Most Influential People

    source: PennMedicine News
  • Patient Voices: Pancreatic Cancer

    Patient Voices: Pancreatic Cancer

    source: New York Times
  • US: New Mexico Passes Step Therapy Reform Legislation

    US: New Mexico Passes Step Therapy Reform Legislation

    source: National Psoriasis Foundation
  • “Oral Parity”: Reducing the Cost of Cancer Care

    “Oral Parity”: Reducing the Cost of Cancer Care

    source: Scientific American
  • About
    • Our Story
    • Awards & Recognition
    • Celgene History
    • Our Culture
    • Our Employees
    • Leadership
    • Compliance
    • Corporate Reports
    • Diversity
    • Global Office Locations
  • Global Office Locations
    • Celgene Worldwide Markets
    • Contact Us
  • Celgene Czech Republic
  • Celgene Portugal
  • Diseases
    • Acute Myeloid Leukemia
    • Beta Thalassemia
    • Indolent NHL
    • Multiple Myeloma
    • Multiple Sclerosis
    • Myelodysplastic Syndromes
    • Myelofibrosis
    • Pancreatic Cancer
    • Psoriasis and Psoriatic Arthritis
  • Therapies
    • Safety Data Sheets
    • Anti-counterfeiting
  • Research & Development
    • Pipeline
    • Medical Innovation
    • R&D Locations
    • Celgene Incubator
    • Research Oncology
    • Clinical Trials
    • Celgene Global Drug Safety and Risk Management
    • Pre-Approval Access
    • Celgene Medical Affairs
    • Registry Studies
  • Responsibility
    • Our Approach
    • Patients First
    • Pre-Approval Access
    • Patient Support
    • Global Health
    • Employees and Communities
    • Environment
    • Business with Integrity
    • Funding
  • Celgene Impact Innovation Awards
    • Previous Innovation Impact Award Winners
  • Previous Innovation Impact Award Winners
    • 2017 Innovation Impact Winners
    • 2016 Innovation Impact Winners
    • 2015 Innovation Impact Winners
    • 2014 Innovation Impact Winners
    • 2013 Innovation Impact Winners
  • Celgene Cancer Care Links™
    • 2018 Celgene Cancer Care Links™ Program Grant Recipients
    • Celgene Cancer Care Links™ Application Process
    • Frequently Asked Questions
    • Press Release
  • Value
    • Value and Innovation Framework Report
    • Celgene Pricing Principles
    • Celgene Patient-Centered Principles on Value Assessments
    • Value of Medical Innovation
  • Newsroom
    • Media Contacts
    • Multimedia Library
    • Press Releases
    • Cellular Immunotherapies
  • Patients
    • Celgene Patient Support®
    • Online Patient Resources
    • REMS – Pharmacy Network
    • Glossary
  • Medical Professionals
    • Celgene Medical Information
  • Partnering
    • Philosophy to Partnering
    • Areas of Interest
    • Partner with Celgene
  • Investors
  • Careers
  • Contact Us – Mobile Shared Services
  • Site Map
  • #9111 (no title)
  • New Features in 2017
  • Celgene Privacy Policy
    • Celgene General Privacy Policy
    • Health Care Professionals Privacy Notice
    • Privacy Contact Us
  • The Value and Cost of Medical Innovation
    • Return to Value
  • Specialty-tiered Pricing Keeps Innovative Treatments for Seriously Ill Patients Out of Reach
    • Return to Value
  • Innovative Therapies Require Healthcare Financing Solutions to Match
    • Return to Value
  • Breakthrough Medications Save Money and Lives
    • Return to Value

Search Newsroom

Media Requests

If you are a member of the press, please submit a question to our Corporate Affairs team here.

Submit a Media Inquiry

Press Releases

See all press releases 

Stay up to date

Sign up to receive the latest investor news and information from Celgene.

Sign Up

Twitter Feed

Tweets by @Celgene

Sign Up

Most Read

  • Moving Mountains: How One Multiple Myeloma Patient Defied the Odds

  • Rare Disease Forces Abrupt Career Change

  • The Human Rights Campaign Foundation Names Celgene Best Place to Work for LGBTQ Equality for 2019

Follow Celgene

  • Celgene on Twitter
  • Celgene on Facebook
  • Celgene on LinkedIn
  • Celgene on YouTube
  • Celgene on Pinterest

About Celgene

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing treatments for our patients.

Global Network

world map

HAVE A QUESTION OR CONCERN?
CONTACT US

  • Site Map
  • About
  • Therapies
  • Research & Development
  • Research Oncology
  • Celgene Corporate Responsibility
  • Newsroom
  • Pipeline
  • Value Hub
  • Patients
  • Medical Professionals
  • Partnering
  • Investors
  • Careers
  • Copyright © 2019 Celgene Corporation
  • Celgene Privacy Policy
  • Terms of Use
  • Newsroom
    • Media Contacts
    • Multimedia Library
      • REMS Fact Sheet
      • Chrysalis Fact Sheet
      • Celgene Position Papers
    • Press Releases
    • Cellular Immunotherapies
X

You are now leaving www.CELGENE.com, a website provided by Celgene. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Celgene does not endorse and/or influence the content found on websites not owned/operated by Celgene.

Continue
To view Website
Cancel
To return to www.Celgene.com

These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).

Continue
To view Website
Cancel
To return to www.Celgene.com
X

The CSR synopses posting is for informational purposes only and is not intended to have any legally binding effect.

Continue Go Back